Current treatment guidelines recommend using cancer antigen-125 (CA-125) as a diagnostic marker for ovarian cancer recurrence, but a recent study suggests CA-125 has poor concordance with progressive ...

The accuracy of the cancer antigen (CA)–125 test in predicting ovarian cancer varies by ethnicity, primarily due to factors like age and comorbidities rather than ethnicity itself. General ...

Cancer Antigen 125 (CA-125) testing shows 23% lower odds of elevated levels in American Indian and Black patients with ovarian cancer compared with White patients. Patients with false-negative CA-125 ...

Many investigators have attempted to codify what degree of CA-125 elevation can predict progression of ovarian cancer with acceptable specificity and sensitivity. Although this serologic approach to ...

The likelihood of having an elevated CA-125 level at ovarian cancer diagnosis was lower for American Indian, Asian, or Black patients versus White patients. HealthDay News — Black and American Indian ...

Please provide your email address to receive an email when new articles are posted on . CA-125 is a “useful test” for ovarian cancer in primary care, especially in symptomatic women aged older than 50 ...

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study finds. It’s the latest example of medical tests that contribute to health ...

The value of the serum tumour marker CA 125 to date has been in the monitoring of ovarian cancer patients for response to therapy and for recurrence of disease. However, despite the availability of ...

About The Study: In this cohort study of patients with ovarian cancer, American Indian and Black patients were 23% less likely to have an elevated cancer antigen (CA)-125 level at diagnosis. Current ...

The molecular evolution of prostate cancer cell line exosomes with passage number. Role of the p38αMAPK in the prognosis and prediction of response to neoadjuvant chemotherapy in locally advanced ...

On World Ovarian Cancer Day 2026, experts explain why ovarian cancer remains difficult to detect early. Silent symptoms, lack of reliable biomarkers and limits of current tests continue to challenge ...